Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab

Hematologic

This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Hematologic
III
Satyanarayana, Gowri
NCT03392142
VICCCTT1876

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: